NeuroBo Pharmaceuticals Inc expected to post a loss of 89 cents a share - Earnings Preview

MetaVia

08/11/2024 15:49

* NeuroBo Pharmaceuticals Inc  NRBO.OQ   NRBO.O  is expected
to show no change in quarterly revenue when it reports  results 
for the period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for NeuroBo Pharmaceuticals
Inc is
for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 22.1%
in the last three months. ​
    * Wall Street's median 12-month price target for NeuroBo
Pharmaceuticals Inc is $22.00​, above​ its last closing price
of $2.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.77       -0.73      -0.55     Beat    24.7
 Jan. 1 0001   -1.06       -1.12      -1.85     Missed  -64.7
 Mar. 31 2024  -3.79       -3.63      -1.32     Beat    63.6​
 Dec. 31 2023  -0.79       -0.78      -2.28     Missed  -190.4
 ​​Jan.        -0.86       -0.86      -0.72     Beat    15.9
 1 0001                                                 
 Jun. 30 2023  -1.01       -1.01      -0.16     Beat    84.1​
 Mar. 31 2023              -5.04      -0.77     Beat    84.8
 Dec. 31 2022  -9.60       -9.60      -14.56    Missed  -51.7
 This summary was machine generated November 8 at 15:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)